Sorafenib is highly effective in suppressing EVs containing mRNA encoding CD63 and TGFB1 by CD90+ CSCs, which may be related to the ability of sorafenib to prolong overall survival in advanced HCC patients and suppress de novo metastasis. This evidence concerns the gene CD63 and hepatocellular carcinoma.